USE OF ANTIBODY AGAINST CD20 TYPE II WITH INCREASED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) IN COMBINATION WITH CYCLOPHOSPHAMIDE, VINCRISTINE, AND DOXORUBICIN FOR TREATMENT OF NON-HODGKIN LYMPHOMA

摘要

The invention relates to the use of the humanized B-Lyl (B-HH6-B-KV1 GE) antibody with the variable region of the heavy chain (VH) represented in SEQ ID NO: 7 and the variable region of the light chain represented in SEQ ID NO: the humanized B-Lyl antibody constructed using glycoengineering techniques, at least 40 % of oligosaccharides in Fc-region are non-fucosilated. The said antibody is proposed as the component for preparing anticancer agent wherein CD20 is expressed in combination with at least one chemotherapeutic agent selected from the group comprising Cyclophosphamide, Vincristine, and Doxorubicin. The treatment with anti-CD20 type II is provided in combination with a) Cyclophosphamide and Vincristine, b) Doxorubicin, c) Cyclophosphamide, d) Cyclophosphamide, Vincristine, and Doxorubicin.